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background:  Anticoagulation with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) is recommended for patients 
with atrial fibrillation (AF) and additional risk factors for stroke, regardless of the pattern of AF.
Methods:  GLORIA-AF collected data on antithrombotic therapy choices for patients with newly identified AF at risk of stroke in course 
of routine care. Phase II began after the first NOAC became available for stroke prevention in AF. This cross-sectional analysis assesses 
treatment in relation to CHA2DS2VASc scores and the pattern of AF among patients in North America during the first 2 years after approval 
of dabigatran etexilate.
Results:  3,415 patients with recent diagnosis of AF and CHA2DS2VASc scores ≥1 were enrolled between Nov 2011 and Feb 2014. 
Median age was 71 years; 44.8% were female, 80.4% had hypertension, 27.1% diabetes mellitus and 86.2% had CHA2DS2VASc scores 
≥2. AF was classified as paroxysmal in 65.9% (n=2250), persistent in 29.5% (n=1009) and permanent in 4.6% (n=156) of patients. 
Relationships of initial antithrombotic therapy to AF pattern and stroke risk are shown.
conclusion:  Initial antithrombotic therapy diverged from guideline recommendations. Patients with paroxysmal AF were less often 
anticoagulated than those with persistent or permanent AF, and more than 22% of patients with paroxysmal AF at high stroke risk were 
untreated or given aspirin alone.
 
